Salix Pharmaceuticals Ltd (SLXP)

172.81
0.16 0.09
NASDAQ : Health Care
Prev Close 172.65
Open 172.72
Day Low/High 172.71 / 172.96
52 Wk Low/High 86.00 / 172.98
Volume 4.30M
Avg Volume 3.38M
Exchange NASDAQ
Shares Outstanding 64.25M
Market Cap 11.10B
EPS -6.53
P/E Ratio N/A
Div & Yield N.A. (N.A)
Salix Pharmaceuticals To Present At Three Investment Conferences In June

Salix Pharmaceuticals To Present At Three Investment Conferences In June

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at three investment conferences during June 2014.

First Week Of January 2015 Options Trading For Salix Pharmaceuticals (SLXP)

First Week Of January 2015 Options Trading For Salix Pharmaceuticals (SLXP)

Investors in Salix Pharmaceuticals Ltd saw new options begin trading this week, for the January 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Salix Pharmaceuticals Larger Than S&P 500 Component DENTSPLY International

Salix Pharmaceuticals Larger Than S&P 500 Component DENTSPLY International

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Salix Pharmaceuticals Ltd was identified as having a larger market cap than the smaller end of the S&P 500, for example DENTSPLY International, Inc. , according to The Online Investor.

Salix Pharmaceuticals Reports 1Q2014 Results

Salix Pharmaceuticals Reports 1Q2014 Results

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

Salix Pharmaceuticals To Present At Two Investment Conferences In May

Salix Pharmaceuticals To Present At Two Investment Conferences In May

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during May 2014.

Salix Pharmaceuticals Outlines Data Presentations At Digestive Disease Week 2014

Salix Pharmaceuticals Outlines Data Presentations At Digestive Disease Week 2014

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that presentations related to the investigation of one of the Company’s products are scheduled to take place during Digestive Disease Week DDW2014 ®.

Insider Trading Alert - SCSS, SLXP And VNTV Traded By Insiders

Insider Trading Alert - SCSS, SLXP And VNTV Traded By Insiders

Stocks with insider trader activity include SCSS, SLXP and VNTV

Salix Pharmaceuticals Announces 1Q2014 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 1Q2014 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report first quarter 2014 financial results following the close of the U.

First Week of June 21st Options Trading For Salix Pharmaceuticals (SLXP)

First Week of June 21st Options Trading For Salix Pharmaceuticals (SLXP)

Investors in Salix Pharmaceuticals Ltd saw new options become available this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SLXP options chain for the new June 21st contracts and identified one put and one call contract of particular interest.

Investing lessons from the biotech rout

Investing lessons from the biotech rout

This is a month that tested my investment skills.

Salix Pharmaceuticals To Present At ROTH Conference

Salix Pharmaceuticals To Present At ROTH Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the 26 th Annual ROTH Conference in Laguna Niguel, CA on Tuesday, March 11, 2014 at 1:30 p.

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Winner

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Winner

Salix Pharmaceuticals was a winner within the health care sector, rising $2.82 (2.6%) to $110.74 on average volume

New Lifetime High For Salix Pharmaceuticals (SLXP)

New Lifetime High For Salix Pharmaceuticals (SLXP)

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a new lifetime high candidate

Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Post-Market Leader Stock

Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a post-market leader candidate

Salix Pharmaceuticals Reports 4Q2013 And FY2013 Results

Salix Pharmaceuticals Reports 4Q2013 And FY2013 Results

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced financial and operating results for the fourth quarter and full year ended December 31, 2013 and other business updates, including the Company’s financial ...

Salix Wins Napo Pharmaceuticals Litigation

Salix Wins Napo Pharmaceuticals Litigation

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that a New York State Supreme Court jury has entered a verdict in its favor in a lawsuit filed against Salix by Napo Pharmaceuticals relating to Fulyzaq™ ...

Salix And Pharming Announce Extension Of PDUFA Action Date For RUCONEST®

Salix And Pharming Announce Extension Of PDUFA Action Date For RUCONEST®

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Pharming Group NV (NYSE Euronext:PHARM) today announced that the Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Action Date to...

Drug Stocks Rally: Consider These Profitable Stocks as Pharmaceutical Deals Rise

Drug Stocks Rally: Consider These Profitable Stocks as Pharmaceutical Deals Rise

Mary Lynn Cesar, Kapitall: Will Actavis's announced $25 billion purchase of Forest Labs increase the appeal of drug stocks? Leading generic drug company Actavis (ACT) [...]

Salix Pharmaceuticals Announces 4Q And FY2013 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 4Q And FY2013 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year 2013 financial results following the close of the U.

Short Interest In Salix Pharmaceuticals Jumps 15.5%

Short Interest In Salix Pharmaceuticals Jumps 15.5%

The most recent short interest data has been released by the NASDAQ for the 01/31/2014 settlement date, which shows a 957,160 share increase in total short interest for Salix Pharmaceuticals Ltd , to 7,140,471, an increase of 15.48% since 01/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin

Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the United States Patent and Trademark Office has issued U.

Salix Announces Acceptance Of NDA Filing For Budesonide Foam In Patients With Distal Ulcerative Colitis

Salix Announces Acceptance Of NDA Filing For Budesonide Foam In Patients With Distal Ulcerative Colitis

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) for Budesonide 2 mg Rectal Foam for the induction of remission...

Contrarian Investing Led Me to Salix Pharmaceuticals

Contrarian Investing Led Me to Salix Pharmaceuticals

If this company can stay on its current trajectory it has nearly 92% upside potential.

Fulyzaq® (crofelemer) 125 Mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea In Adult Patients Living With HIV On ART Therapy

Fulyzaq® (crofelemer) 125 Mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea In Adult Patients Living With HIV On ART Therapy

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that HIV Clinical Trials, an international, peer-reviewed journal focused on human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome...

Salix Pharmaceuticals (SLXP) Hits New Lifetime High

Salix Pharmaceuticals (SLXP) Hits New Lifetime High

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a new lifetime high candidate

Salix Pharmaceuticals Provides Post-Merger Update

Salix Pharmaceuticals Provides Post-Merger Update

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today provided an update regarding business operations and FY2014 revenue and EPS guidance.

Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at The 32 nd Annual J.

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Laggard

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Laggard

Salix Pharmaceuticals was a leading decliner within the health care sector, falling $1.17 (-1.3%) to $89.26 on average volume